Market cap
₹220 Cr
Revenue (TTM)
₹135 Cr
P/E Ratio
--
P/B Ratio
-4.9
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -25.43 | 144.45 | 19.23 | 66.93 | 13.81 |
| EBIT | -120.00 | 99.08 | 36.85 | 4.58 | -227.07 |
| Net Profit | -23.42 | 65.51 | 9.66 | -0.02 | -253.41 |
| EPS | -23.42 | 65.56 | 10.44 | 15.94 | -201.34 |
| Book Value | -- | -- | -66.48 | 18.05 | 11.07 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| -19.69 | -17.77 | -7.52 | -15.61 | -12.29 |
| Net Margin
| -11.20 | -14.38 | -10.06 | -15.51 | -9.31 |
| Return on equity
| 0.00 | 0.00 | -- | 0.00 | 0.00 |
| Return on Capital
| -36.03 | -31.05 | -- | -33.53 | -32.89 |
| Return on Assets
| -14.46 | -14.47 | -13.41 | -20.42 | -16.57 |
| Debt to Equity (x)
| -- | -- | -1.76 | -2.57 | -2.43 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
--
|
-33.53
|
-32.89
|
-41.69
|
-50.32
|
|
Peer Median
|
--
|
15.74
|
14.72
|
18.85
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
10.86
|
13.75
|
11.67
|
14.92
|
--
|
ROA
-13.41
Lower than Peers by 20.15
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
-13.41
|
-20.42
|
-16.57
|
-6.40
|
-27.09
|
|
Peer Median
|
6.74
|
8.17
|
7.86
|
9.06
|
--
|
EBIT Margin
-7.52
Lower than Peers by 20.21
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
-7.52
|
-15.61
|
-12.29
|
-31.17
|
-29.59
|
|
Peer Median
|
12.69
|
14.78
|
15.03
|
14.71
|
--
|
Net Margin
-10.06
Lower than Peers by 18.92
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
-10.06
|
-15.51
|
-9.31
|
-8.77
|
-37.32
|
|
Peer Median
|
8.86
|
8.54
|
9.33
|
8.49
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
--
|
-13.50
|
-6.12
|
-2.07
|
-30.72
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
19.23
Higher than Peers by 11.09
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
19.23
|
3.37
|
175.71
|
27.93
|
-48.80
|
|
Peer Median
|
8.14
|
14.12
|
10.27
|
11.85
|
--
|
EBIT Growth
36.85
Higher than Peers by 19.60
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
36.85
|
-31.30
|
-8.67
|
-34.78
|
-7,849.79
|
|
Peer Median
|
17.24
|
21.59
|
24.15
|
28.00
|
--
|
Net Profit Growth
9.66
Lower than Peers by 7.19
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
9.66
|
-70.63
|
-195.99
|
69.93
|
-1,795.44
|
|
Peer Median
|
16.85
|
28.31
|
30.29
|
36.51
|
--
|
EPS Growth
10.44
Lower than Peers by 0.16
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
10.44
|
-70.62
|
-167.98
|
87.25
|
-1,795.28
|
|
Peer Median
|
10.60
|
14.25
|
24.50
|
--
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
--
|
-66.48
|
-23.96
|
55.23
|
-33.41
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
-1.76
Lower than Peers by 1.81
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
-1.76
|
-2.57
|
-2.43
|
-2.77
|
-1.47
|
|
Peer Median
|
0.04
|
0.20
|
0.23
|
0.20
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
--
|
-0.74
|
-1.56
|
-0.37
|
-0.11
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.60
Lower than Peers by 1.12
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
0.60
|
0.60
|
0.36
|
0.72
|
0.76
|
|
Peer Median
|
1.72
|
1.83
|
1.79
|
1.96
|
--
|
Quick Ratio
0.26
Lower than Peers by 0.92
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
0.26
|
0.26
|
0.12
|
0.31
|
0.40
|
|
Peer Median
|
1.17
|
1.23
|
1.47
|
1.44
|
--
|
Interest Coverage
-1.50
Lower than Peers by 9.37
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
-1.50
|
-3.59
|
-5.43
|
-7.70
|
-6.65
|
|
Peer Median
|
7.86
|
8.41
|
9.42
|
8.58
|
--
|
Operating Efficiency
Debtors to sales
7.44
Lower than Peers by 18.35
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
7.44
|
8.88
|
4.66
|
18.57
|
32.79
|
|
Peer Median
|
25.79
|
25.29
|
25.82
|
26.12
|
--
|
Asset Turnover
1.33
Higher than Peers by 0.67
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
1.33
|
1.31
|
1.76
|
0.73
|
0.73
|
|
Peer Median
|
0.67
|
0.73
|
0.75
|
0.77
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
--
|
24.43
|
20.80
|
80.66
|
69.12
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
--
|
80.66
|
57.15
|
117.03
|
111.83
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
--
|
140.38
|
99.66
|
254.01
|
229.85
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
--
|
-35.29
|
-21.70
|
-56.32
|
-48.90
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
-16.20
Lower than Peers by 55.96
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
-16.20
|
--
|
--
|
--
|
--
|
|
Peer Median
|
39.76
|
39.76
|
39.70
|
33.48
|
--
|
Price / Book Value
-4.91
Lower than Peers by 9.12
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
-4.91
|
-4.19
|
-11.48
|
-4.69
|
-1.13
|
|
Peer Median
|
4.21
|
4.21
|
3.72
|
4.21
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.10
|
0.10
|
0.16
|
0.21
|
--
|
EV/EBITDA
-41.71
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
-41.71
|
-19.06
|
-41.90
|
-15.97
|
-16.88
|
|
Peer Median
|
--
|
28.23
|
30.23
|
29.90
|
--
|
Market Cap
220
Lower than Peers by 7,164
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Oxygenta Pharma
|
220
|
179
|
294
|
97
|
52
|
|
Peer Median
|
7,384
|
5,844
|
4,851
|
2,099
|
--
|